Skip to main content
Premium Trial:

Request an Annual Quote

Ariana Pharma, CTCLS Ink Distribution Deal for Japan

NEW YORK (GenomeWeb News) – Ariana Pharma announced today an exclusive distribution deal with CTC Laboratory Systems covering Japan.

The terms of the deal call for CTCLS to distribute Ariana's KEM data analytics software and services technology. CTCLS, based in Tokyo, is an R&D service provider, specializing in the pharmaceutical sector.

Further details of the deal were not disclosed.

KEM, short for Knowledge Extraction and Management, is an association rules-based data analytical technology. It finds patient responder "subpopulations and biomarker signatures that statistical methods are unable to detect," according to Ariana, which has offices in Paris and in Cambridge, Mass.

"This deal with CTCLS will provide an excellent entry into Asia and the world's third largest biotechnology market," Mohammad Afshar, president and CEO of Ariana, said in a statement. "We expect the ongoing growth of Japanese companies in medicine development, diagnostics, and biomarker studies will further increase demand for Ariana’s KEM software."

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.